These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33442785)

  • 21. Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model.
    Lin YC; Kuo JY; Hsu CC; Tsai WC; Li WC; Yu MC; Wen HW
    Int J Pharm; 2013 Jan; 441(1-2):381-8. PubMed ID: 23220078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
    Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
    J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
    Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
    Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
    Pinto AC; Moreira JN; Simões S
    Prostate; 2011 Jan; 71(1):81-90. PubMed ID: 20607721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations.
    Pinto AC; Angelo S; Moreira JN; Simões S
    J Nanosci Nanotechnol; 2012 Mar; 12(3):2891-900. PubMed ID: 22755139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer.
    Xu G; Yang D; Ding H; Zhong L; Zhu J; Mi X; Zhang X; Wu Z; Xin W; Li C; Wang J; Fang L
    Eur J Clin Pharmacol; 2024 Sep; 80(9):1399-1407. PubMed ID: 38904799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A solvent-assisted active loading technology to prepare gambogic acid and all-trans retinoic acid co-encapsulated liposomes for synergistic anticancer therapy.
    Na K; Liu K; Yu J; Wang X; Li M; Tian C; He H; He Y; Wang Y
    Drug Deliv Transl Res; 2020 Feb; 10(1):146-158. PubMed ID: 31529371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes.
    Chang RS; Kim J; Lee HY; Han SE; Na J; Kim K; Kwon IC; Kim YB; Oh YK
    Nanomedicine; 2010 Dec; 6(6):769-76. PubMed ID: 20570638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendrimer encapsulated and conjugated delivery of berberine: A novel approach mitigating toxicity and improving in vivo pharmacokinetics.
    Gupta L; Sharma AK; Gothwal A; Khan MS; Khinchi MP; Qayum A; Singh SK; Gupta U
    Int J Pharm; 2017 Aug; 528(1-2):88-99. PubMed ID: 28533175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
    Lim HJ; Parr MJ; Masin D; McIntosh NL; Madden TD; Zhang G; Johnstone S; Bally MB
    Clin Cancer Res; 2000 Nov; 6(11):4449-60. PubMed ID: 11106266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer.
    Wang X; Liu Y; Xu W; Jia L; Chi D; Yu J; Wang J; He Z; Liu X; Wang Y
    Drug Deliv Transl Res; 2021 Oct; 11(5):2186-2197. PubMed ID: 33452654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LHD-Modified Mechanism-Based Liposome Coencapsulation of Mitoxantrone and Prednisolone Using Novel Lipid Bilayer Fusion for Tissue-Specific Colocalization and Synergistic Antitumor Effects.
    Hu T; Cao H; Yang C; Zhang L; Jiang X; Gao X; Yang F; He G; Song X; Tong A; Guo G; Gong C; Li R; Zhang X; Wang X; Zheng Y
    ACS Appl Mater Interfaces; 2016 Mar; 8(10):6586-601. PubMed ID: 26907854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Stern ST; Barenholz Y; Gabizon A
    J Drug Target; 2016 Nov; 24(9):878-889. PubMed ID: 27187807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomes in the treatment of malignancy: a clinical perspective.
    Sugarman SM; Perez-Soler R
    Crit Rev Oncol Hematol; 1992; 12(3):231-42. PubMed ID: 1497823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity.
    Gao L; Zhang L; He F; Chen J; Zhao M; Li S; Wu H; Liu Y; Zhang Y; Ping Q; Hu L; Qiao H
    Int J Nanomedicine; 2021; 16():3581-3598. PubMed ID: 34079251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone.
    Ghanbarzadeh S; Arami S; Pourmoazzen Z; Ghasemian-Yadegari J; Khorrami A
    J Biomater Appl; 2014 Jul; 29(1):81-92. PubMed ID: 24336315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
    Yang J; Shi Y; Li C; Gui L; Zhao X; Liu P; Han X; Song Y; Li N; Du P; Zhang S
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):637-46. PubMed ID: 25034977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment.
    Wong MY; Chiu GN
    Anticancer Drugs; 2010 Apr; 21(4):401-10. PubMed ID: 20110806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.